|
Puerto Rico Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Puerto Rico Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Puerto Rico .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Puerto Rican pharmaceutical and healthcare industry.
Competitive intelligence, Puerto Rican pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Puerto Rican market.
The Puerto Rico Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- 2013 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Puerto Rico Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Puerto Rican pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Puerto Rico to test other views – a key input for successful budgeting and strategic business planning in the Puerto Rican pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Puerto Rican Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Puerto Rico .
- Exploit The Latest Competitive Puerto Rican Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Puerto Rico .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- 2013 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Puerto Rico Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Puerto Rico Pharmaceuticals And Healthcare Industry SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Pharmaceutical Business Environment Ratings Q209 |
| Limits to Potential Returns |
| Risks to Realisation of Returns |
Chapter - Market Summary |
| Regulatory Regime |
| Pricing and Reimbursement Issues |
| Tax Incentives |
| Table: Puerto Rico – Incentives, Benefits And Discounts For Pharmaceutical Manufacturers |
| Trade Accords |
Chapter - Industry Developments |
| Epidemiology |
| Healthcare Sector |
| Healthcare Financing |
| Healthcare Reforms |
| Pharmaceutical Industry |
| Table: Puerto Rico: Multinational Downscaling |
| Pharmaceutical Production |
| Plant Closures |
| Recent Company Developments |
| Pharmaceutical Wholesale and Distribution |
| Research and Development |
| Biotechnology |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Puerto Rico – Drug Market Indicators, 2003-2013 |
| Key Growth Factors – Industry |
| Table: Puerto Rico – Health Expenditure Indicators, 2003-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Puerto Rico: Historical Data and Forecasts |
| Prescription Market Forecast |
| Table: Puerto Rico – Prescription Market Indicators, 2003-2013 (US$mn unless otherwise indicated) |
| OTC Drug Market Forecast |
| Table: Puerto Rico – OTC Market Indicators, 2003-2013 (US$mn unless otherwise indicated) |
| Patented Drug Market Forecast |
| Table: Puerto Rico – Patented Market Indicators, 2003-2013 |
| Generic Drug Market Forecast |
| Table: Puerto Rico – Generic Drug Market Indicators, 2003-2013 |
| Export/Import Forecasts |
| Table: Puerto Rico – Pharmaceuticals Exports And Imports, 2003-2013 (US$mn unless otherwise indicated) |
| Other Healthcare Data Forecasts |
| Table: Puerto Rico – Other Healthcare Data, 2003-2013 |
| Medical Device Market Forecast |
| Table: Puerto Rico Medical Device Market Forecast 2006-2013 (US$mn unless otherwise stated) |
| Key Risks to BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Monitor |
| Pfizer |
| GlaxoSmithKline |
| Merck & Co |
| Abbott Laboratories |
| Novartis |
| Sanofi-Aventis |
| Eli Lilly |
Chapter - Country Snapshot: Puerto Rico Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education and Healthcare |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market and Spending Power |
| Table: Employment Indicators, 1999-2004 |
| Table: Average Annual Manufacturing Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Puerto Rico Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
For BMI’s Puerto Rico Pharmaceutical and Healthcare Q209 report, we have forecast the total drug marketing spending to increase from US$2.9bn in 2008 to US$4.1bn by 2013, representing a compound annual growth rate (CAGR) of 7.1% in US dollar terms. We believe the main drivers for growth include the prevalence of cheaper over-the-counter (OTC) and generic drugs that are increasingly available in retail outlets at cheaper prices. Meanwhile, patented medicine will continue to experience positive growth as the island’s dominant manufacturing presence will influence consumer preferences.
According to our Business Environment Rankings, Puerto Rico’s pharmaceutical and healthcare sector has reached second place in our regional America’s rankings, ahead of Canada. Favourable scores on all fronts makes Puerto Rico a low risk area for multinational drugmakers looking to invest in the island. However, we note most do this to exploit the international export potential and not to directly market pharmaceuticals within Puerto Rico.
During January 2009, the global delivery company DHL opened a new section of its existing facility in Puerto Rico, dedicated to the controlled and safe storage of medical devices and pharmaceuticals. As the country is home to several multinationals that operate manufacturing plants with a high export volume, BMI believes that the new DHL centre will be expected to cater to their increasing storage and distribution demands. Another delivery service provider, UPS, has also announced plans to construct a similar regulated storage facility in San Juan in late 2009.
Recent activity in January 2009 by Japanese drugmaker Daiichi Sankyo has resulted in the opening of an office in Puerto Rico, which BMI believes will result in increased revenue for the firm. The epidemiological profile of the country includes hypertension and diabetes, which we consider to complement Daiichi Sankyo’s product portfolio and may have influenced its decision to locate there.
|
Puerto Rico Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |